Infusion Rate Standardization: A Data-Driven Approach to Developing Institutional Standards

At a large NCI-designated Cancer Center, standard infusion rates for the administration of cryopreserved Immune Effector Cells (IEC) do not exist in policy. Current practice is to start slowly and increase the rate per patient tolerance. Limited literature is available on rate and administration methods for cryopreserved IECs. While some FDA package inserts define administration methods and infusion rates, most defer to institutional standards. The lack of a national standard has resulted in cancer institutions across the U.S. adopting varying methods. The objective of this retrospective analysis was to propose a standard institutional rate. The nurse educator performed a gap analysis involving a comprehensive literature review, benchmarking with comparable centers, and retrospective data collection. The literature review used search terms: cryopreserved cells, Dimethyl sulfoxide (DMSO), infusion rate, and adverse events. Clinical nurse specialists, pharmacists, and nurse educators from five comparable cancer centers participated in interviews to benchmark administration practices. To assess current institutional practice, the nurse educator collected data on 121 patients who received cryopreserved IECs over the past year at their center. Variables included method of administration, product type, FDA approval status, DMSO concentration, volume infused, infusion time, adverse reactions (AE), and interventions. All AEs were graded using CTCAE criteria. Due to variability in infusion across patients and products, rates were calculated for each administration using volume and completion time to determine mean rates. Benchmarking confirmed the inconsistency of IEC administration methods and rates. While some institutions use fixed rates (e.g., 10 ml/min), others use total time (e.g., infuse over 10 minutes). Administration methods included gravity, syringe push, mechanical pump, and filter use. Although the literature review did not offer guidance on IEC administration, experts have provided robust guidance on hematopoietic stem cells (HSC), which some institutions consider a comparable product. DMSO was a significant AE contributor, with higher volumes and concentrations of DMSO associated with increased AE frequency. Data collected by the nurse educator showed an average gravity infusion rate of 5.89 ml/min and syringe push, 2.23 ml/min. Slowing infusion rates resolved DMSO side effects without pharmacological intervention, with one grade 4 AE requiring infusion termination. Following this analysis, the nurse educator's institution is evaluating the use of fixed infusion rates and mechanical pumps for IEC and HPC products. The findings highlight an opportunity for institutional collaboration to align best practice guidelines. Standardizing administration practices can improve patient outcomes and support the advancement of IEC therapies in oncology.